HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PlanetRx.com

This article was originally published in The Tan Sheet

Executive Summary

Eight-for-one reverse stock split cleared, keeping company on NASDAQ, e-tailer announces Dec.1. Shareholders also approve doubling of number of common shares and authorize access to $50 mil. in equity financing from Alpha Venture Capital. The e-tailer cut operating costs and laid off 70 employees this summer (1"The Tan Sheet" Oct. 30, p. 12 and 2June 19, In Brief)

You may also be interested in...



HealthCentral Strives For More; Drugstore.com, PlanetRx Turn To Cuts

Visitors to e-health provider more.com are now being redirected to HealthCentral.com following the buyout by Emeryville, Calif.-based HealthCentral.

PlanetRx.com

Cost-saving measures include layoffs of 70 employees, evenly split between the online drugstore's San Francisco headquarters and Memphis, Tenn. distribution center the week of June 5, as well as reductions in ad spending. PlanetRx.com, which currently has approximately 380 employees, plans no further staff cuts. The firm says it is moving toward meeting its goal of total cash expenditure reduction of 8%-12%, announced at the end of the first quarter. Also, chief technology officer James Chong has resigned and will not be replaced

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel